Idiopathic pulmonary fibrosis (IPF) is a progressive disease with a dismal prognosis. The
average life expectancy of untreated patients with IPF is only 3 to 4 years. Decline in forced …

Cardiac fibrosis is central to the pathology of heart failure, particularly heart failure with
preserved ejection fraction (HF p EF). Irrespective of the underlying profibrotic condition (eg …

Inflammation and fibrosis are two pathological features of chronic kidney disease (CKD).
Transforming growth factor-β (TGF-β) has been long considered as a key mediator of renal …

Pirfenidone (PFN) is an anti-fibrotic drug with significant anti-inflammatory property used for
treatment of fibrotic conditions such as idiopathic pulmonary fibrosis (IPF). In the coronavirus …

Pirfenidone (PFD) is a pharmacological compound with therapeutic efficacy in idiopathic
pulmonary fibrosis. It has been chiefly characterized as an antifibrotic agent, although it was …

Fibrosis and cancer is described by some epidemiological studies as chronic stages of
different disease conditions typically characterized by uncontrolled accumulation of extra …

Respiratory diseases are among the leading causes of morbidity and mortality worldwide,
coupled with the ongoing coronavirus disease 2019 (COVID-19) pandemic. mRNA lipid …

Aim SARS-CoV-2 infection has been divided by scientific opinion into three phases: the first
as asymptomatic or slightly symptomatic and the second and the third with greater severity …

Idiopathic pulmonary fibrosis (IPF) is an advancing and fatal lung disease with increasing
incidence and prevalence. Nintedanib and pirfenidone were approved by the FDA for the …

We assessed safety and tolerability of treatment with pirfenidone (1602–2403 mg· day− 1)
and nintedanib (200–300 mg· day− 1) in patients with idiopathic pulmonary fibrosis (IPF) …